This paper is in the following e-collection/theme issue:

Public Health Informatics (93) Clinical Information and Decision Making (1407) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (156)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/49811, first published .
Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study

Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study

Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study

Authors of this article:

Ashley A Holdefer1 Author Orcid Image ;   Jeno Pizarro1 Author Orcid Image ;   Patrick Saunders-Hastings2 Author Orcid Image ;   Jeffrey Beers1 Author Orcid Image ;   Arianna Sang1 Author Orcid Image ;   Aaron Zachary Hettinger3, 4 Author Orcid Image ;   Joseph Blumenthal3 Author Orcid Image ;   Erik Martinez1 Author Orcid Image ;   Lance Daniel Jones1 Author Orcid Image ;   Matthew Deady1 Author Orcid Image ;   Hussein Ezzeldin5 Author Orcid Image ;   Steven A Anderson5 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Ashley A Holdefer   1 , MS ;   Jeno Pizarro   1 , BBA ;   Patrick Saunders-Hastings   2 , PhD ;   Jeffrey Beers   1 , MD ;   Arianna Sang   1 , BA ;   Aaron Zachary Hettinger   3, 4 , MS, MD ;   Joseph Blumenthal   3 , BA ;   Erik Martinez   1 , MBA ;   Lance Daniel Jones   1 , MA ;   Matthew Deady   1 , BA ;   Hussein Ezzeldin   5 , PhD ;   Steven A Anderson   5 , PhD

1 IBM Consulting, Bethesda, MD, United States

2 Accenture Inc, Ottawa, ON, Canada

3 Center for Biostatistics, Informatics and Data Science, MedStar Health Research Institute, Columbia, MD, United States

4 Department of Emergency Medicine, Georgetown University School of Medicine, Washington, DC, United States

5 Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, United States

Corresponding Author:

  • Hussein Ezzeldin, PhD
  • Center for Biologics Evaluation and Research
  • United States Food and Drug Administration
  • 10903 New Hampshire Avenue
  • Silver Spring, MD, 20993
  • United States
  • Phone: 1 2404028629
  • Email: Hussein.Ezzeldin@fda.hhs.gov